AstraZeneca

EQS-News: Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Retrieved on: 
Wednesday, April 10, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Sale, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Pharma, Hypoparathyroidism, Fine chemical

Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Key Points: 
  • Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
    The issuer is solely responsible for the content of this announcement.
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • The company led by Thierry Abribat and an exceptional management team has developed innovative therapies for rare endocrine diseases.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Directorate change

Retrieved on: 
Wednesday, April 10, 2024
Justine, AstraZeneca, Aquaculture, Operations director, Interim, Arthur Andersen, Finance, United Utilities

Justine joined OTAQ in July 2023 as Interim Chief Financial Officer.

Key Points: 
  • Justine joined OTAQ in July 2023 as Interim Chief Financial Officer.
  • Prior to this, she held a number of senior positions in a range of high growth companies across various sectors including property development, aviation charter services, IT and construction.
  • Most recently Justine was Managing Director of GB3 Limited, an IT Managed Services company, having joined the company in 2012 as Finance and Operations Director.
  • Before GB3 Limited, Justine worked for United Utilities and AstraZeneca having previously qualified as a Chartered Accountant with Arthur Andersen.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, CBNK

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Empire, AstraZeneca, Integration, Sale, Capital, DOMA, CBNK, CVR, Security (finance)

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • Under the terms of the agreement, DOMA shareholders are expected to receive $6.29 in cash per share they own.
  • Capital Bancorp, Inc. (Nasdaq: CBNK ), relating to its proposed merger with Integrated Financial Holdings, Inc.
  • Under the terms of the agreement, CBNK shareholders are estimated to receive $5.36 in cash and 1.115 shares of Capital common stock per share they own.

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Retrieved on: 
Monday, April 8, 2024
EGFR, Patient, Anaplastic lymphoma kinase, Research, Alectinib, Active ingredient, Lung cancer, AACR, AstraZeneca, ALK, Vaccine

Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC. The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.

Key Points: 
  • The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.
  • In addition, NXP900 demonstrated potent, single agent, antiproliferative activity in anaplastic lymphoma kinase (ALK)-resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells.
  • Alectinib is the active ingredient in AlecensaTM, an ALK inhibitor approved for the treatment of NSCLC.
  • Moreover, effective inhibition of signaling pathways associated with osimertinib and alectinib resistance were observed in the respective cell lines tested.

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, AstraZeneca, Merck, Cancer, Doctor of Philosophy, Spacecraft, B7-H4, Antibody, Johnson & Johnson, Immunotoxin, CSO, MedImmune

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.

Key Points: 
  • BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
  • As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
  • “We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug conjugates,” said Solomon Langermann, PhD, NextCure’s chief scientific officer.
  • “Rakesh is a world authority on ADCs and has an incredible record of researching and developing them.

AAFA's Advocacy for Health Equity Leads to White House Address on Asthma Inhaler Pricing

Retrieved on: 
Wednesday, April 3, 2024
AAFA, Conditional sentence, AstraZeneca, Health equity, Part, GSK, Boehringer Ingelheim, Patient, Asthma, Medicare (United States), Medicaid, Medicare, Inflation, Government

The White House invited AAFA President and CEO, Kenneth Mendez, and Jenna Riemenschneider, AAFA Senior Director of Policy and Advocacy, in recognition of the advocacy group’s work to advance health equity for people with asthma.

Key Points: 
  • The White House invited AAFA President and CEO, Kenneth Mendez, and Jenna Riemenschneider, AAFA Senior Director of Policy and Advocacy, in recognition of the advocacy group’s work to advance health equity for people with asthma.
  • “On behalf of the 27 million people in the United States with asthma, we appreciate the leadership of President Biden and Senator Sanders to bring down costs for asthma treatments.
  • Pricing announcements made in March by some manufacturers of inhalers will mean lower costs and improved access to asthma medicine for many people with asthma starting this June,” stated Mendez.
  • “Lower out-of-pocket costs have the potential to drastically improve asthma health outcomes.

ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

Retrieved on: 
Tuesday, April 2, 2024
Clinical research, Molecular medicine, AstraZeneca, Entrepreneurship, Patient, SAN, Mayo Clinic, Research, RNA, Bachelor of Science, Lead, University, MD, Senior, Sympathetic nervous system, Biology, Therapy, Destiny, Division, CMO, Amgen, DSM-IV codes, Pharmaceutical industry

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).
  • As CMO, Dr. Storgard will lead Clinical Research, Clinical Operations, Biometrics, Pharmacovigilance and Medical Affairs.
  • Dr. Storgard has a BSc in biology and an MD from the University of Saskatchewan in Canada.
  • Dr. Storgard completed a fellowship in rheumatology at Scripps Clinic and Research Center in San Diego, CA.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ADTH, LABP, FUSN

Retrieved on: 
Monday, April 1, 2024
AbbVie, AstraZeneca, Sale, Fraud, Advertising, Security (finance)

If you are an AdTheorent shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an AdTheorent shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)

Retrieved on: 
Monday, April 1, 2024
AbbVie, AstraZeneca, THL, ABBV, IPO, Thomas H. Lee Partners, Brodsky, AZN, CVR, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, AdTheorent will be acquired by Cadent, LLC (“Cadent”).
  • The Company’s common stockholders will receive cash consideration of $3.21 per share.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Fulvestrant, NMPA, AstraZeneca, Disease, Progression-free survival, CDX, Boehringer Ingelheim, Patient, Webcast, NGS, Hospital, Breast, Breakthrough, Safety, HR, Depreciation, ID, Precision, Food, Marketing, FDA, Cryptocurrency

Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.

Key Points: 
  • Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.
  • Total value of new contracts entered into during 2023 amounted to RMB310 million, representing a 24% increase from 2022.
  • Revenues were RMB121.1 million (US$17.1 million) for the three months ended December 31, 2023, representing a 14.9% decrease from RMB142.2 million for the same period in 2022.
  • Burning Rock will host a conference call to discuss the fourth quarter and full year 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on March 29, 2024.